Douglass Winthrop Advisors LLC Has $8.75 Million Position in Zoetis Inc. $ZTS

Douglass Winthrop Advisors LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 87.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 59,796 shares of the company’s stock after selling 420,151 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Zoetis were worth $8,749,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Zoetis during the 2nd quarter valued at $814,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.6%

Shares of ZTS opened at $119.82 on Thursday. The stock’s 50-day moving average price is $125.75 and its two-hundred day moving average price is $132.31. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $172.23. The company has a market capitalization of $50.58 billion, a PE ratio of 19.90, a PEG ratio of 1.84 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the prior year, the firm posted $1.40 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZTS. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Bank of America raised their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.